DAX23.527 -0,5%ESt505.442 -0,3%Top 10 Crypto15,35 -4,1%Dow46.421 +0,2%Nas22.794 +0,7%Bitcoin95.505 -2,8%Euro1,1799 +0,5%Öl66,60 -0,1%Gold3.747 +1,7%

Protagonist Therapeutics Aktie

Kaufen

Verkaufen

54,00 EUR +1,50 EUR +2,86 %

20:30:12

BER

63,39 USD +1,17 USD +1,88 %

21:29:24

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

Bei einem anderen Broker handeln Smartphone

Smartphone

Marktkap.3,30 Mrd. EUR

KGV9,13Div. Rendite0,00%

WKNA2AP32

ISINUS74366E1029

SymbolPTGX

Protagonist Therapeutics Aktien News

Sortieren:Datum Meistgelesen

17.09.25BenzingaDemystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews

17.09.25BenzingaThis Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

12.09.25BenzingaThis Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

07.08.25BenzingaWhat 4 Analyst Ratings Have To Say About Protagonist Therapeutics

06.08.25ZacksProtagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

03.06.25Benzinga9 Analysts Assess Protagonist Therapeutics: What You Need To Know

07.05.25ZacksProtagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

25.03.25ZacksWall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

12.03.25ZacksProtagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

10.03.25BenzingaWhy Is Protagonist Therapeutics Stock Trading Higher On Monday?

03.03.25BenzingaTakeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

21.02.25ZacksProtagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

13.11.24ZacksProtagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

07.11.24ZacksProtagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

15.10.24ZacksProtagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

27.06.24PR NewswireProtagonist Therapeutics Set to Join S&P SmallCap 600

12.05.23PR NewswireProtagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

11.05.23PR NewswireProtagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference

11.05.23PR NewswireProtagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association

04.05.23PR NewswireProtagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update

07.03.23PR NewswireProtagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis

21.12.22PR NewswireProtagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

01.12.22PR NewswireProtagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit

16.11.22PR NewswireProtagonist Therapeutics Reports Granting of Inducement Award

08.11.22PR NewswireProtagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update

03.11.22PR NewswireProtagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting

02.11.22PR NewswireProtagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

Protagonist Therapeutics News

Protagonist Therapeutics News: auf dieser Seite finden Sie alle Protagonist Therapeutics News und Nachrichten zur Protagonist Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Protagonist Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Protagonist Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.